JPRN-UMIN000015861已完成未知
The test of the improvement effect for eyestrain of the Bilberry extracts - The test of the improvement effect for eyestrain of the Bilberry extracts
niversal Clinical Systems Co., Ltd.0 个研究点目标入组 20 人开始时间: 2014年12月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 60years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Subjects who have previous medical history of drug and/or food allergy. 2)Subjects who have previous medical history and/or current medical history of serious diseases (e.g., diabetes, digestive organ, liver, pancreas, heart and/or kidney). 3)Subjects who have been enrolled in the other clinical trials within about last 1 month. 4)Subjects who predicted gluttony and irregular eating habits by the pre-questionnaire and doctor's questions. 5)Subjects who constantly use supplements and/or functional foods affecting eyestrain. 6)Subjects who take medicines and plan to take new health foods. 7)Others who have been determined ineligible by principal investigator or sub-investigator.
研究者
相似试验
已完成
不适用
Verification of eye fatigue suppression effect by ingesting test foods. A placebo-controlled, Simple Randomization, double blind, cross over trial.healthy adultJPRN-UMIN000037406School of Allied Health Sciences, Kitasato University50
尚未招募
不适用
Verification of eye fatigue suppression effect by ingesting test foods. A placebo-controlled, Simple Randomization, open, cross over trial.healthy adultJPRN-UMIN000031400otte Co., Ltd.10
已完成
不适用
The test of the effect for eyestrain of the Bilberry extractsEyestrainJPRN-UMIN000015351niversal Clinical Systems Co., Ltd.30
已完成
不适用
A study of reducing discomfort in the eyes and nose after consuming herb powder when pollen from Cryptomeria japonica (known as sugi in Japanese) is dispersed. A double-blind, parallel group comparison studyHealthy adultsJPRN-UMIN000039247imeQ RD inc.28
已完成
不适用
Study on the improvement of ocular function by continuous ingestion of foodJPRN-UMIN000035920HUMA R&D CORP60